Johnson & Johnson Services, Inc., AbbVie Inc. and GC Aesthetics are Dominating the Asia-Pacific Breast Reconstruction Market in 2019

Asia-Pacific Breast Reconstruction Market is expected to grow with the CAGR of 9.0% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report @

Asia-Pacific breast reconstruction market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in Asia-Pacific breast reconstruction market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement into the market. This helped companies to maximize the sales with enhanced product portfolio. For instance In September 2020, POLYTECH Health & Aesthetics GmbH launched additional shapes and surfaces - B-Lite with MESMO fine-texturing surface and B-Lite with the unique Microthane shell coating. These new product launched by the company has expanded its B-Lite breast implant product portfolio leading to increased sales and revenue in future.

Johnson & Johnson Services, Inc. is the dominating player in Asia-Pacific breast reconstruction market. The other key players existing in the market includes AbbVie Inc., GC Aesthetics, POLYTECH Health & Aesthetics GmbH, AirXpanders, Inc., CEREPLAS, DPS Technology Development Ltd, Integra LifeSciences, KOKEN CO., LTD., LABORATORIES ARION, PMT Corporation, Shanghai Kangning Medical Supplies Ltd., Sientra, Inc. and Wanhe among others.

Asia-Pacific Breast Reconstruction MarketJohnson Services, Inc.

Johnson Services, Inc. was incorporated in 1887 and is headquartered in New Jersey, U.S. The company is engaged in the research and development, manufacturing and sale of the broad range of products in the health care field. The company is providing products under consumer health products, medical devices, and pharmaceutical products. The market focus products lie under medical devices product category. The company is taking various strategic initiatives in order to expand its business in the market.

  • In March 2019, Johnson & Johnson Services, Inc.’s brand Mentor received Food and Drug Administration (FDA) approval for the MemoryShape device under Premarket Approval (PMA) Application. This has helped the company in expanding their portfolio in the breast reconstruction implant market.

The company has wide presence across Asia-Pacific, Europe, Middle East and Africa, Asia-Pacific and South America. The company has various subsidiaries such as Acclarent, Inc. (U.S.), Ethicon Endo-Surgery, Inc. (U.S.), Actelion Pharmaceuticals Japan Ltd. (Japan), AMO Belgium BVBA (Belgium) and AMO Germany GmbH (Germany) among more.

AbbVie Inc.

AbbVie Inc. is headquartered in Illinois, U.S. was founded in 2013. The company is company is a research-driven biopharmaceutical company which is engaged in providing therapeutics for the areas including immunology, oncology and neuroscience among more. The company has multiple business segments such as US specialized therapeutics, US general medicine, international and other, in which US specialized therapeutics is the market focused segment. The company is providing products under central nervous system, eye care, gastroenterology, medical aesthetics and other. The market focus products lie under medical aesthetics product category. The company is engaged in expanding its business via various strategic initiatives.

  • In July 2017, AbbVie Inc., announced that its subsidiary, Allergan Sales LLC acquired Keller Medical, which is creator of the Keller Funnel used in breast augmentation and reconstruction procedures. The Keller Funnel is a shape of cone which reduces surgeon and patient contact during the procedures. This silicone gel implants allows the surgeons to use “no touch technique”, this technique minimizes the bacteria and foreign material in the surgical area. This acquisition has strengthened the medical aesthetics business of the company.

The company has wide presence across Europe, Asia-Pacific, South America, Asia-Pacific and Middle East and Africa. The company also has various subsidiary companies such as AbbVie Holdings Inc. (U.S.), AbbVie Pty Ltd (Australia), AbbVie SA (Belgium), AbbVie Farmacêutica Ltda. (Brazil) and AbbVie Productos Farmacéuticos Limitada (Chile) among others.

GC Aesthetics:

GC Aesthetics is headquartered in Dublin, Ireland. The company is engaged in the development and distribution of breast implants used in the aesthetic breast implant surgery or breast reconstruction procedures. The company is engaged in providing products in categories such as GCA Consultation Kit, Eve 4.0, Breast Implants, PERLE, Gluteal Implants, HydroCone and Noa, all of them are the market focused categories.

The company has wide presence across Latin America, Europe, Asia-Pacific, Middle East and Africa. The company has developed innovative products to increase its market presence and demand.

For instance-

  • In October 2020, GC Aesthetics launched a novel round breast implant named PERLE with BioQ– Surface technology and highly cohesive Emunomic Breast Tissue Dynamic Gel. This new product launched by the company during the emergence of COVID-19 has increased its credibility in the market.